Chemotherapy Combination for Pancreatic Cancer
Trial Summary
What is the purpose of this trial?
The standard or usual treatment for this disease consists of two chemotherapy drugs gemcitabine and nab-paclitaxel given together.
Research Team
Derek Jonker
Principal Investigator
Ottawa Hospital Research Institute, ON Canada
Eligibility Criteria
This trial is for adults with metastatic pancreatic ductal adenocarcinoma who haven't had treatment for their advanced disease. They must have measurable disease, be in good health otherwise, and not have used certain drugs before. Participants need to provide tissue and blood samples, complete quality of life questionnaires, use effective contraception if childbearing potential exists, and be able to follow the trial procedures.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Gemcitabine and Nab-Paclitaxel, with or without Durvalumab and Tremelimumab, until progression or unacceptable toxicity
Follow-up
Participants are monitored for overall survival and progression-free survival
Treatment Details
Interventions
- Durvalumab
- Gemcitabine
- Nab-paclitaxel
- Tremelimumab
Durvalumab is already approved in European Union, United States, Japan for the following indications:
- Locally advanced, unresectable non-small cell lung cancer (NSCLC)
- Extensive-stage small cell lung cancer (ES-SCLC)
- Limited-stage small cell lung cancer (LS-SCLC)
- Locally advanced or metastatic urothelial carcinoma
- Not specified in provided sources
Find a Clinic Near You
Who Is Running the Clinical Trial?
Canadian Cancer Trials Group
Lead Sponsor
AstraZeneca
Industry Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology